Mode
Text Size
Log in / Sign up

Case report details treatment of ANCA-associated vasculitis with Evans syndrome and cerebral infarction in a 72-year-old woman

Case report details treatment of ANCA-associated vasculitis with Evans syndrome and cerebral…
Photo by Pawel Czerwinski / Unsplash
Key Takeaway
Consider early ANCA testing in cryptogenic stroke with systemic involvement to balance immunosuppression and infection risk.

This publication is a case report and literature review focusing on a single 72-year-old female patient. The patient presented with ANCA-associated vasculitis, Evans syndrome, and cerebral infarction. She received a combination of corticosteroids, intravenous immunoglobulin, therapeutic plasma exchange, and cyclophosphamide within a hospital setting. The sample size is one, and the study phase is not reported.

Regarding outcomes, renal and hematological parameters stabilized during the treatment course. However, neurological deficits and thrombocytopenia persisted despite the intervention. No specific effect sizes, absolute numbers, p-values, or confidence intervals are provided for these results. The primary outcome was not reported in the source material.

Safety data indicate a SARS-CoV-2 infection occurred during the reported period. No other adverse events, serious adverse events, discontinuations, or tolerability issues were explicitly detailed beyond this infection. The authors acknowledge that early ANCA testing in cryptogenic or progressive stroke with systemic involvement is vital. Management requires a careful balance between immunosuppression and infection risk. This case highlights the complexity of treating such conditions in elderly patients.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic autoimmune disease, and central nervous system involvement, though uncommon, can be a severe manifestation. The co-occurrence of AAV and Evans syndrome (ES) is exceptionally rare and may reflect broader immune dysregulation. A 72-year-old female presented with progressive right-sided hemiplegia and mixed aphasia. Imaging revealed multiple acute cerebral infarcts. Laboratory findings showed anemia, thrombocytopenia, acute kidney injury, and elevated inflammatory markers. Serology confirmed myeloperoxidase (MPO)-ANCA positivity, supporting a diagnosis of AAV, most consistent with microscopic polyangiitis. Subsequent hematological workup supported concurrent autoimmune cytopenias consistent with probable ES. Despite corticosteroids and intravenous immunoglobulin, her condition deteriorated with left middle cerebral artery occlusion; during hospitalization, this deterioration coincided with a SARS-CoV-2 infection. Management was escalated to therapeutic plasma exchange and cyclophosphamide. This regimen stabilized renal and hematological parameters, although severe neurological deficits and thrombocytopenia persisted. This case highlights that stroke may be a catastrophic presenting feature of AAV and that concurrent autoimmune cytopenias may add substantial diagnostic and therapeutic complexity. Early ANCA testing in cryptogenic or progressive stroke with systemic involvement is vital, and management requires careful balance between immunosuppression and infection risk.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.